Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor

Journal of Theoretical Biology

Volumn 251, Issue 3, 2008, Pages 541-551

  Mohanty, Utkala ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Antiretroviral therapy; Intravenous administration; Multiple dose pharmacokinetics; Subcutaneous administration

Indexed keywords

ENFUVIRTIDE;

ASSESSMENT METHOD; DOSE-RESPONSE RELATIONSHIP; DRUG; EQUATION; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITOR; KINETICS; MODELING;

ARTICLE; CELL MEMBRANE; DRUG ABSORPTION; DRUG DIFFUSION; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STEADY STATE; TARGET CELL;

AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 40849126556     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2007.12.017     Document Type: Article

References (33)

1. Bird R.B., Stewart W.E., and Lightfoot E.N. Transport Phenomena (2002), Wiley, Singapore
2. Crank J. The Mathematics of Diffusion (1980), Oxford University Press, London
3. Dixit N.M., and Perelson A.S. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J. Theor. Biol. 226 (2004) 95-109
4. Dixit N.M., and Perelson A.S. Influence of drug pharmacokinetics on HIV pathogenesis and therapy. In: Wu H., and Tan W.Y. (Eds). Deterministic and Stochastic Models on AIDS and HIV with Intervention (2005), World Scientific Press, Singapore 287-311
5. Dixit N.M., Markowitz M., Ho D.D., and Perelson A.S. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir. Ther. 9 (2004) 237-246
6. Fuzeon. Fuzeon Summary of Product Characteristics (2003), Roche Registration Limited
7. Fuzeon, 2003b. Fuzeon Clinical Pharmacology and Biopharmaceutics Reviews, Part 2. 〈http://www.fda.gov/cder/foi/nda/2003/21481_Fuzeon_BioPharmr_P2.pdf〉 (accessed 26.10.07).
8. Gradshteyn I.S., and Ryzhik I.M. Table of Integrals, Series, and Products (1994), Academic Press, New York
9. Hammer S.M., Saag M.S., Schechter M., Montaner J.S.G., Schooley R.T., Jacobsen D.M., Thompson M.A., Carpenter C.C.J., Fischl M.A., Gazzard B.G., Gatell J.M., Hirsch M.S., Katzenstein D.A., Richman D.D., Vella S., Yeni P.G., and Volberding P.A. Treatment for adult HIV infection-2006 recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 296 (2006) 827-843
10. Katlama, C., Walmsley, S., Hicks, C., Cahn, P., Neubacher, D., Villacian, J., Investigators, f.t.R., 2006. Tipranavir achieves twice the rate of treatment response and prolongs durability of response vs comparator PI in ART-experienced patients, independent of baseline CD4 cell count or viral load: week 48 RESIST 1 and 2 combined analyses. In: Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
11. Kepler T.B., and Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. USA 95 (1998) 11514-11519
12. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Mathews T., Johnson M.R., Nowak M.A., Shaw G.M., and Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4 (1998) 1302-1307
13. Lalezari J.P., Patel I.H., Zhang X.P., Dorr A., Hawker N., Siddique Z., Kolis S.J., and Kinchelow T. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J. Clin. Virol. 28 (2003) 217-222
14. Lalezari J.P., Eron J.J., Carlson M., Cohen C., DeJesus E., Arduino R.C., Gallant J.E., Volberding P., Murphy R.L., Valentine F., Nelson E.L., Sista P.R., Dusek A., and Kilby J.M. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17 (2003) 691-698
15. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S.G., Piliero P.J., Trottier B., Walmsley S., Cohen C., Kuritzkes D.R., Eron Jr. J.J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M., and Group T.S. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348 (2003) 2175-2185
16. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H., Delfraissy J., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., and Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348 (2003) 2186-2195
17. Lu J., Deeks S.G., Hoh R., Beatty G., Kuritzkes B.A., Martin J.N., and Kuritzkes D.R. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J. Acquir. Immune. Defic. Syndr. 43 (2006) 60-64
18. Mosekilde E., Jensen K.S., Binder C., Pramming S., and Thorsteinsson B. Modeling absorption kinetics of subcutaneous injected soluble insulin. J. Pharmacokinet. Biop. 17 (1989) 67-87
19. Mould D.R., Zhang X.P., Nieforth K., Salgo M., Buss N., and Patel I.H. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin. Pharmacol. Ther. 77 (2005) 515-528
20. Nucci G., and Cobelli C. Models of subcutaneous insulin kinetics. A critical review. Comput. Methods Prog. Biol. 62 (2000) 249-257
21. Oldfield V., Keating G.M., and Plosker G. Enfuvirtide-a review of its use in the management of HIV infection. Drugs 65 (2005) 1139-1160
22. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2 (2002) 28-36
23. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
24. Poveda E., Rodes B., Lebel-Binay S., Faudon J.-L., Jimenez V., and Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J. Clin. Virol. 34 (2005) 295-301
25. Pozniak A., Saag M., Bellos N., Chiliade P., Grinsztejn B., Molina J.-M., Katlama C., Meyer S.D., Vangeneugden T., Lefebvre E., and Hill A. Efficacy of TMC114/r in treatment-experienced HIV patients: factors influencing outcome in the pooled 24-week analysis of POWER 1,2 and 3. HIV Med. 7 (2006) 1
26. Stocker H., Kloft C., Plock N., Breske A., Kruse G., Herzmann C., Schulbin H., Kreckel P., Weber C., Goebel F., Roeling J., Staszewski S., Plettenberg A., Moecklinghoff C., Arasteh K., and Kurowski M. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob. Agents Ch. 50 (2006) 667-673
27. Supersaxo A., Hein W.R., and Steffen H. Effect of molecular-weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7 (1990) 167-169
28. Thompson M., DeJesus E., Richmond G., Wheeler D., Flaherty J., Piliero P., True A., Chiu Y.Y., Zhang Y., McFalls E., Miralles G.D., and Patel I.H. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. AIDS 20 (2006) 397-404
29. van den Broek I., Sparidans R.W., Huitema A.D.R., Schellens J.H.M., and Beijnen J.H. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 837 (2006) 49-58
30. Wach P., Trajanoski Z., Kotanko P., and Skrabal F. Numerical approximation of mathematical-model for absorption of subcutaneously injected insulin. Med. Biol. Eng. Comput. 33 (1995) 18-23
31. Wahl L.M., and Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. P. Roy. Soc. Lond. B Biol. 267 (2000) 835-843
32. Wei X.P., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., and Shaw G.M. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 373 (1995) 117-122
33. Zhang X.P., Nieforth K., Lang J.M., Rouzier-Panis R., Reynes J., Dorr A., Kolis S., Stiles M.R., Kinchelow T., and Patel I.H. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin. Pharmacol. Ther. 72 (2002) 10-19